VRDN Stock: Viridian Therapeutics, Inc. Stock Price, Analysis & Insights

Get live VRDN stock price $15.66, comprehensive Viridian Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time VRDN stock data and investment insights.

Quick links:Financial Metrics•Earnings•Analyst Forecasts•Financials•Technicals

15.66

3.99%Today

VRDN • Viridian Therapeutics, Inc. • NASDAQ Capital Market • Healthcare

Market Cap

1.41B

Volume

396.61K

52W High

34.29

52W Low

13.18

Loading chart data...

Investment Score

Annual (latest period)

Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

View full dashboardUnlock quarterlyFaster signals · Pro+

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through...

Contact Information

Website: https://www.viridiantherapeutics.com
Address: 221 Crescent Street
Country: US

Investment Analysis & Business Insights

Healthcare

Biotechnology

Investment Highlights

✓ Strong presence in the Healthcare sector with established market position

Important Investment Considerations

⚠All investments carry risk, including potential loss of principal for Viridian Therapeutics, Inc. shareholders
⚠Market volatility can significantly impact stock price, especially for smaller companies
⚠Sector-specific risks in Healthcare may affect company performance
⚠Past performance does not guarantee future results for Viridian Therapeutics, Inc.
⚠Investors should consider how Viridian Therapeutics, Inc. fits within their overall portfolio allocation
⚠Valuation metrics suggest potential, but require fundamental analysis

Market Cap

1.41B

P/E Ratio (TTM)

-4.67

Beta

0.90

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

Related Stocks

Compare VRDN with peer companies:

Celldex Therapeutics, Inc. (CLDX)

Price: $29.49
Market cap: 1.96B

Cogent Biosciences, Inc. (COGT)

Price: $31.31
Market cap: 5.35B

Edgewise Therapeutics, Inc. (EWTX)

Price: $33.26
Market cap: 3.58B

Galapagos N.V. (GLPG)

Price: $27.98
Market cap: 1.84B

Structure Therapeutics Inc. (GPCR)

Price: $41.56
Market cap: 2.39B

ImmunityBio, Inc. (IBRX)

Price: $7.14
Market cap: 7.47B

Ocular Therapeutix, Inc. (OCUL)

Price: $8.38
Market cap: 1.83B

uniQure N.V. (QURE)

Price: $26.18
Market cap: 1.65B

Arcus Biosciences, Inc. (RCUS)

Price: $21.99
Market cap: 2.21B

Vera Therapeutics, Inc. (VERA)

Price: $32.05
Market cap: 2.30B

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.